AOD-9604 Fasted Morning Protocol

AOD-9604 is a synthetic peptide modeled after the C-terminal fragment of human growth hormone, specifically amino acids 176 to 191. It was developed by Metabolic Pharmaceuticals in Australia during the late 1990s and early 2000s. The original goal was to isolate the fat-burning properties of HGH without triggering the blood sugar changes, water retention, and joint pain that come with full growth hormone use. The peptide went through clinical trials for obesity. A Phase IIb trial in 2004 showed modest but measurable fat loss effects. The FDA did not approve it as a drug, which is partly why it ended up in the peptide research and wellness space rather than as a prescription medication. Australia's regulatory body, the TGA, also declined approval for commercial sale as a pharmaceutical. Despite the failed drug pathway, AOD-9604 has remained available as a research peptide and has gained a following for targeted fat loss, particularly around the face and chin area where diet and exercise have limited impact.

AOD-9604 works by mimicking the fat-mobilizing segment of growth hormone without activating the growth-promoting or insulin-resistance pathways. It stimulates lipolysis, which is the breakdown of stored fat, and inhibits lipogenesis, which is the creation of new fat cells. The peptide binds to receptors on fat cells and triggers the release of stored triglycerides into the bloodstream where they can be used as energy. This process is enhanced when insulin levels are low, which is why the fasted morning protocol is recommended. Taking AOD-9604 on an empty stomach gives it the best conditions to mobilize fat without competing signals from food intake. Unlike full HGH, AOD-9604 does not raise IGF-1 levels significantly. It does not affect blood sugar regulation or thyroid function. This makes it a safer option for people who want the fat loss effects of growth hormone without the metabolic risks. The submental chin fat application is popular because the face is one of the first places people notice changes, and chin fat is notoriously resistant to diet and exercise. AOD-9604 does not target the chin specifically, but the overall fat reduction can make a visible difference in this area.

Fat loss with AOD-9604 is real but slow. This is not a rapid transformation peptide. Users typically notice changes after four to six weeks of consistent use, with more meaningful results appearing between weeks eight and twelve. The fat loss tends to show up first in the midsection and face. Belly fat, love handles, and under-chin fat respond well because these areas are metabolically active and store fat in a way that is accessible to lipolysis signals. Arms and legs respond less dramatically. Energy levels may increase slightly as the body shifts toward using stored fat for fuel. Some users report feeling less hungry in the morning, which is likely related to the fat mobilization providing a steady energy supply. AOD-9604 does not cause muscle loss, which is a problem with some aggressive fat loss approaches. It also does not cause the edema or joint pain that full HGH users sometimes experience. The lack of growth-promoting effects means it will not help with muscle building either, so it is purely a fat loss tool. The difference between AOD-9604 and full HGH fragment is that AOD-9604 is specifically designed to avoid the growth and metabolic side effects. A full HGH fragment would carry the same risks as growth hormone therapy, including insulin resistance and acromegaly risk at high doses. AOD-9604 strips those away and keeps only the fat metabolism component.

A user on r/Peptides shared: “I started AOD-9604 mainly because I had this stubborn pocket of fat under my chin that would not go away no matter how lean I got. I did the fasted morning protocol, 300 mcg subQ right when I woke up, then waited 30 minutes before eating. By week six my jawline looked sharper. By week ten the double chin was basically gone. It was slow but it worked.“ Another user on r/Peptides noted: “The effects were subtle. I did not feel different day to day, but my pants got looser and my face looked leaner in photos. The biggest thing was that I did not get any of the side effects I was worried about, no water retention, no joint pain, nothing. It was just a slow, steady change.“ Most users describe the experience as uneventful in terms of how they feel. The changes show up in the mirror and on the scale rather than in energy or mood.

• Gradual reduction in stubborn body fat, especially around the midsection
• Visible improvement in facial definition and submental chin fat
• No significant impact on blood sugar or insulin sensitivity
• Minimal side effects compared to full growth hormone therapy
• No water retention, joint pain, or carpal tunnel symptoms
• Can be used alongside other peptides without interaction issues

CJC-1295 without DAC and Ipamorelin are common additions. These boost growth hormone levels through a different mechanism, and the combination can accelerate fat loss while adding the benefits of higher GH like better sleep and skin quality. Standard doses are 100 to 200 mcg of each at bedtime. BPC-157 can be stacked for gut health and healing support. There is no interaction between BPC-157 and AOD-9604, so they are safe to use together. The glow protocol, GHK-Cu plus TB-500 plus BPC-157, can be combined with AOD-9604 if you want both fat loss and skin improvement. This is a common combination for people doing a full body recomposition protocol. Tirzepatide or semaglutide users sometimes add AOD-9604 for additional fat mobilization, but this should be done under medical supervision since GLP-1 agonists already affect appetite and metabolism substantially.